Interleukin 1 or tumor necrosis factor-α: Which is the real target in rheumatoid arthritis?

Journal of Rheumatology

Volumn 29, Issue SUPPL. 65, 2002, Pages 10-15

  Dayer, Jean Michel ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Apolipoprotein A I; CD40; Cell cell interactions rheumatoid arthritis; Interleukin I; Tumor necrosis factor

Indexed keywords

APOLIPOPROTEIN A1; CD11B ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ARTICLE; CELL INTERACTION; CYTOKINE PRODUCTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MACROPHAGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; FEMALE; HOSPITALIZATION; IMMUNOLOGY; MALE; METABOLISM; MOUSE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-1; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036729083     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis
2. Anti-cytokine therapy for rheumatoid arthritis
3. Cytokine pathways and joint inflammation in rheumatoid arthritis
4. Major role for interleukin-1 but not tumor necrosis factor in early cartilage damage in immune complex arthritis in mice
5. Anticytokine treatment of established type II collagen-induced arthritis in DBA/I mice: A comparative study using anti-TNF-α, anti-IL-1α/β, and IL-1ra
6. Different roles of tumor necrosis factor-α and interleukin-1 in murine streptococcal cell wall arthritis
7. Uncoupling of inflammatory and destructive mechanisms in arthritis
8. High levels of neutralizing autoantibodies against IL-1α are associated with a better prognosis in chronic polyarthritis: A follow-up study
9. Anti-IL-1α autoantibodies in early rheumatoid arthritis
10. Biologic basis for interleukin-1 in disease
11. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production
12. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor
13. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice
14. Arterial inflammation in mice lacking the interleukin-1 receptor antagonist gene
15. 2 production by human synovial cells
16. Some recombinant human cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures and inhibit it in human articular cartilage cultures
17. Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6
18. Synovial tissue macrophage populations and articular damage
19. Cell-cell interactions in chronic inflammation: Modulation of surrounding cells by direct contact with stimulated T lymphocytes
20. 3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T-cells
21. Expression and cleavage of tumor necrosis factor and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T-cells
22. Human Th1 cells preferentially induce interleukin (IL)-1β while Th2 cells induce IL-1 receptor antagonist production upon cell-cell contact with monocytes
23. CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of interleukin-2 or interleukin-15-driven, contact-dependent, interleukin-1β production by monocytes
24. Cell surface glycoproteins expressed on activated human T-cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
25. Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes
26. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinase 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
27. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis